Bank of America
OCUL icon

Bank of America’s Ocular Therapeutix OCUL Stock Holding History

Bank of America’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.36M Sell
397,092
-204,268
-34% -$1.95M ﹤0.01% 3751
2025
Q4 		$7.3M Buy
601,360
+154,244
+34% +$1.87M ﹤0.01% 3082
2025
Q3 		$5.23M Sell
447,116
-312,144
-41% -$3.73M ﹤0.01% 3964
2025
Q2 		$7.05M Sell
759,260
-183,028
-19% -$1.43M ﹤0.01% 3554
2025
Q1 		$6.91M Buy
942,288
+505,217
+116% +$3.88M ﹤0.01% 3492
2024
Q4 		$3.73M Sell
437,071
-341,400
-44% -$3.33M ﹤0.01% 3861
2024
Q3 		$6.77M Sell
778,471
-257,700
-25% -$2.12M ﹤0.01% 3452
2024
Q2 		$7.09M Buy
1,036,171
+809,118
+356% +$4.99M ﹤0.01% 3286
2024
Q1 		$2.07M Buy
227,053
+140,064
+161% +$994K ﹤0.01% 4432
2023
Q4 		$388K Buy
86,989
+29,923
+52% +$88.5K ﹤0.01% 5667
2023
Q3 		$179K Sell
57,066
-38,038
-40% -$156K ﹤0.01% 5960
2023
Q2 		$491K Buy
95,104
+28,323
+42% +$168K ﹤0.01% 5293
2023
Q1 		$352K Sell
66,781
-31,229
-32% -$148K ﹤0.01% 5598
2022
Q4 		$275K Buy
98,010
+39,975
+69% +$132K ﹤0.01% 5748
2022
Q3 		$240K Buy
58,035
+18,724
+48% +$94.3K ﹤0.01% 5878
2022
Q2 		$158K Sell
39,311
-10,260
-21% -$38.8K ﹤0.01% 6246
2022
Q1 		$246K Sell
49,571
-33,536
-40% -$186K ﹤0.01% 6347
2021
Q4 		$579K Buy
83,107
+30,463
+58% +$237K ﹤0.01% 5742
2021
Q3 		$526K Buy
52,644
+16,606
+46% +$187K ﹤0.01% 5608
2021
Q2 		$511K Sell
36,038
-16,751
-32% -$255K ﹤0.01% 5408
2021
Q1 		$866K Sell
52,789
-6,784
-11% -$131K ﹤0.01% 4964
2020
Q4 		$1.23M Sell
59,573
-69,165
-54% -$1.03M ﹤0.01% 4324
2020
Q3 		$979K Buy
128,738
+43,159
+50% +$358K ﹤0.01% 4226
2020
Q2 		$712K Buy
85,579
+71,692
+516% +$475K ﹤0.01% 4369
2020
Q1 		$68K Sell
13,887
-4,170
-23% -$20.6K ﹤0.01% 5732
2019
Q4 		$72K Buy
18,057
+239
+1% +$831 ﹤0.01% 6128
2019
Q3 		$53K Buy
17,818
+5,964
+50% +$26.7K ﹤0.01% 6305
2019
Q2 		$51K Buy
11,854
+435
+4% +$1.61K ﹤0.01% 6295
2019
Q1 		$45K Sell
11,419
-14,852
-57% -$59.7K ﹤0.01% 6237
2018
Q4 		$105K Buy
26,271
+17,425
+197% +$96K ﹤0.01% 5886
2018
Q3 		$61K Buy
8,846
+2,615
+42% +$16.4K ﹤0.01% 6120
2018
Q2 		$42K Buy
6,231
+3,972
+176% +$27.3K ﹤0.01% 6224
2018
Q1 		$14K Sell
2,259
-419
-16% -$2.36K ﹤0.01% 6498
2017
Q4 		$12K Buy
2,678
+1,533
+134% +$7.83K ﹤0.01% 6570
2017
Q3 		$7K Sell
1,145
-4,382
-79% -$28.2K ﹤0.01% 6638
2017
Q2 		$51K Sell
5,527
-2,255
-29% -$21.8K ﹤0.01% 5866
2017
Q1 		$72K Sell
7,782
-227
-3% -$1.89K ﹤0.01% 5771
2016
Q4 		$67K Buy
8,009
+2,640
+49% +$20.5K ﹤0.01% 5801
2016
Q3 		$37K Buy
5,369
+1,443
+37% +$8.8K ﹤0.01% 5854
2016
Q2 		$20K Buy
3,926
+2,726
+227% +$27K ﹤0.01% 6255
2016
Q1 		$12K Sell
1,200
-3,133
-72% -$23.7K ﹤0.01% 6333
2015
Q4 		$41K Buy
4,333
+3,927
+967% +$42.4K ﹤0.01% 6126
2015
Q3 		$6K Sell
406
-1,254
-76% -$25.2K ﹤0.01% 6711
2015
Q2 		$35K Buy
1,660
+1,637
+7,117% +$40.6K ﹤0.01% 6117
2015
Q1 		$1K Buy
+23
New +$756 ﹤0.01% 6829

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America's OCUL Position: Q1 2026 in Review

Bank of America reduced its Ocular Therapeutix (OCUL) stake by 34% in Q1 2026, selling an estimated $1.95M and leaving 397,092 shares worth $3.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3751.

Bank of America first reported a position in OCUL in Q1 2015 and has held it in 45 quarters since. The position peaked at $7.3M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Bank of America held 397,092 shares of Ocular Therapeutix worth $3.36M as of Q1 2026.
  • Bank of America sold 204,268 Ocular Therapeutix shares in Q1 2026, an estimated $1.95M.
  • Ocular Therapeutix made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3751 holding.
  • Bank of America first reported a position in Ocular Therapeutix in Q1 2015 and has held it in 45 quarters since.
  • Bank of America's Ocular Therapeutix position peaked at $7.3M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.